Breaking News, Collaborations & Alliances

Merck, Galapagos Enter Inflammatory Alliance

Galapagos NV has entered into a multi-year global strategic alliance with Merck, through an affiliate, to develop potential new therapies in inflammatory diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Galapagos NV has entered into a multi-year global strategic alliance with Merck, through an affiliate, to develop potential new therapies in inflammatory diseases. Galapagos will be responsible for the discovery and preclinical development of new small molecule candidate drugs based on Galapagos targets. Merck will have the exclusive option to license each candidate for clinical development and commercialization on a worldwide basis. The alliance will leverage Galapagos’ SilenceSelect t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters